CAMBRIDGE, MA, May 21, 2016 – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinicalstage biopharmaceutical company, today announced positive pre-clinical data supporting CAT- 2054 as a potential treatment for nonalcoholic steatohepatitis (NASH). The data presented compared CAT-2003, an analog of CAT-2054, versus control in a murine metabolic model of NASH followed for up to 16 weeks. The CAT-2000 series are inhibitors of Sterol Regulatory Element-Binding Protein 1 (SREBP1) and SREBP2, master regulators of lipid metabolism. CAT- 2003 demonstrated a significant decrease in gene expression markers of liver inflammation as well as a significant decrease in fibrosis and steatosis. Also seen were significantly reduced ballooning degeneration and significant reduction in the development of pre-neoplastic lesions in the liver, which are precursors to the development of hepatocellular carcinoma. CAT-2054 is an oral product candidate currently in a Phase 2a clinical trial in patients with hypercholesterolemia, ..... read more

Partnering to advance a NASH Therapy

Case Studies

Custom feeding studies in obesity:

Dr. Michael Briggs, Woodland and Dr. Dominic Picarella of Catabasis at Digestive Disease Week in San Diego.

"As a new start up biotech company, there is always a sense of urgency to get data quickly to help us make key program decisions.  In 2016, we needed to perform basic in vivo pharmacology studies and we needed the data in a rapid time frame.  Woodland offered the right expertise and agility to work with us as we refined our study plans.  Their ability to get started quickly, flexibility for study changes and attention to animal health outside normal business hours helped keep our crucial studies on-track. We thank Woodland for helping enable our corporate success."

Responding to the Fast Cycles of Startups

Angus Sinclair, B.Sc., PhD

Senior Director, Oncology

Northern Biologics

Toronto, Canada

www.NorthernBiologics.com

Catabasis, a MA biopharma firm, required an in vivo NASH model to test their compound as a potential therapy and selected Woodland Biosciences to perform the studies.  In addition to data, Catabasis received world-class consulting by Mike Briggs, who was invited to co-present the results at Digestive Disease Week in May, 2016.  Mike Briggs has a long association with SREBP, the Sterol Regulatory Element Binding Protein, a regulatory transcription factor key to the 1985 Nobel Prize for receptor-mediated uptake of LDL cholesterol, and also Catabasis' drug target.


Catabasis press release:  

Customer needed feeding studies to inform the safety and efficacy of a metabolic drug.  The studies required timed dosing and precise necropsy of 31 tissue/organ samples per mouse, at fixed times of 7 and 11AM, 3 and 7 PM, 1 AM and 7 AM.